Positron Joins Exhibitors at MedAxiom Fall Conference to Promote the Attrius, Positron’s Cardiac Optimized PET Scanner
INDIANAPOLIS-(Business Wire)-September 18, 2009 - Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will attend MedAxiom’s Fall Conference in Dana Point, California September 23rd, 2009 to promote their cardiac optimized PET scanner, the Attrius™ (www.medaxiom.com).
The MedAxiom conferences keep its members informed of changing trends, technologies, strategies and best practices in cardiology-practice administration and service delivery. “The MedAxiom Fall Conference attracts a mix of cardiology practice attendees with approximately 75% of current attendees being CEO’s and other high-level administrators, and the other 25% being cardiologists. We now have over 108 practices registered so it looks as though we’re anticipating another great conference,” says Chris Romeo, Vice President of Corporate Relations for MedAxiom.
Since joining the MedAxiom group in July, Positron has introduced and informed the MedAxiom members about current and proposed reimbursement pricings, the clinical and cost efficacy of PET and the benefits of the Attrius™, Positron’s Cardiac PET Scanner. In preparation for the Fall Conference, Positron recently hosted an educational Webinar where MedAxiom members learned about the low cost of entry, lower patient radiation exposure, competitive scan times and the clinical and cost efficacies of Cardiac PET. The members also participated in a thorough Q&A session with Positron’s Clinical Specialists. Peter Webner, RT(N), CNMT Northeast Regional Business Director at Positron states, “The Webinar was a great vehicle to introduce Positron and our message for the upcoming MedAxiom Fall Conference. Positron’s MedAxiom membership has been a tremendous means to reach our target audience and the interest in our products and services are evident. We deliver the best full cardiac solution and look forward for the opportunity to communicate that directly with the administrators, cardiologists and technologists who attend. Mr. Webner further states Positron’s focus has been to inform that Cardiovascular PET imaging enables the Physician to provide better care. In the past, many Cardiologists have not explored Cardiovascular PET due to the size and cost of the oncology-focused PET/CT devices currently on the market. Positron is changing the paradigm. Positron’s Attrius™ provides the opportunity for the Physician to provide superior care with a device that is designed by Cardiologists for Cardiologists. The small footprint, robust standard cardiovascular software package and reasonable price point all make this technology a viable choice for enhancing the capabilities of Cardiovascular practices, while providing better care.”
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
